WT1 126-134 peptide 

WT1 126-134 peptide is a Wilms' tumor oncogene protein (WT1) peptide (RMFPNAPYL). WT1 126-134 peptide is presented by HLA-A0201 and induces cytotoxic CD8 T cells capable of killing WT1+ positive tumor cells. WT1 126-134 can form stable complexes with the H-2Db (mouse) or HLA-A0201 (human) molecules. WT1 126-134 peptide/HLA-A0201 complex has an extremely high affinity (K_d = 0.2 nM) with the humanized monoclonal antibody (IgG1). WT1 126-134 peptide can be used as a vaccine for T cells or as a target for antibodies^[1][2][3].

WT1 126-134 peptide (100 μg, emulsified with incomplete Freund’s adjuvant, i.p., once a week for 2 weeks) induces epitope-specific CTL, but fails to produce a significant anti-tumor effect in the TRAMP-C2 model^[1].
WT1 126-134 peptide (100 μg, emulsified with incomplete Freund’s adjuvant, i.p., once a week for 3 weeks) combined with the auxiliary peptide (WT1_35-52) significantly enhances CTL induction and delays tumor growth induced by mWT1-C1498 cells in mice^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1108.31

C₅₂H₇₇N₁₃O₁₂S

256952-63-3

Arg-Met-Phe-Pro-Asn-Ala-Pro-Tyr-Leu

RMFPNAPYL

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Shirakawa T, Kitagawa K. Antitumor effect of oral cancer vaccine with Bifidobacterium delivering WT1 protein to gut immune system is superior to WT1 peptide vaccine. Hum Vaccin Immunother. 2018 Jan 2;14(1):159-162.

  [2]. David A, et al, A Cytotoxic Human Monoclonal Antibody Recognizing Cell Surface WT1 Peptide/HLA-A2 Complexes. Blood 2011; 118 (21): 1677.

  [3]. Nakajima H, et al. Identification of mouse helper epitopes for WT1-specific CD4+ T cells. Cancer Immunol Immunother. 2021 Nov;70(11):3323-3335.